## AZN: AstraZeneca PLC - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.07 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-6.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($87.65)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. AstraZeneca issues 67,907 shares under employee share plans in latest period**
- Source: Investing.com | 20251202T011028 | Neutral | Relevance: 100%
- AstraZeneca PLC issued 67,907 ordinary shares under its employee share plans between June 1 and November 30, 2025. This action reduced the balance of unallotted shares under these schemes from 3,688,383 to 3,620,476. The issuance was disclosed in an SEC filing and involved various share schemes including the AstraZeneca Share Option Plan.

**2. AstraZeneca Moves Ahead of Mineralys With Fast Baxdrostat Review**
- Source: Citeline News & Insights | 20251203T011028 | Somewhat-Bullish | Relevance: 100%
- AstraZeneca is moving ahead of Mineralys Therapeutics with a fast Baxdrostat review, according to a report from Scrip. This development suggests a competitive landscape in the pharmaceutical industry for new drug approvals. The article hints at potential implications for both companies in the market.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $288.0B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.6 |
| Current P/E | 19.8 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.2% to 0.1% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 (-1.2%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.07% (CS: 53) | Neutral |
| RSI_14 | 61.0 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $90.85
- **Stop Loss:** $87.65 (3.5% risk)
- **Target:** $97.25 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 296
- **Position Value:** $26,891.60
- **Portfolio %:** 26.89%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*